ClinicalTrials.gg
Not yet recruitingNCT07011199Updated Jun 8, 2025

Clinical Outcomes of Early Kasai Surgery With Umbilical Cord MSCs in Biliary Atresia

A Phase 1 interventional study of Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs) and Kasai Portoenterostomy in Biliary Atresia, Kasai Portoenterostomy and Mesenchymal Stem Cell Transplantation, sponsored by Universitas Diponegoro. Not yet recruiting at 1 site in Indonesia. Open to participants aged 0 Days to 90 Days. Per ClinicalTrials.gov, last updated 2025-06-08.

Sponsored by Universitas Diponegoro · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
0 Days to 90 Days
Sex
All
01

Study summary

The goal of this clinical trial with historical control is to evaluate whether umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy can improve clinical outcomes in infants with biliary atresia undergoing Kasai surgery before 90 days of age.

The main questions it aims to answer are:

Does UC-MSC therapy improve liver function parameters (bilirubin, albumin, liver enzymes, coagulation profile)? Does UC-MSC therapy reduce complications such as anemia, ascites, jaundice, and improve PELD scores? Does UC-MSC therapy improve overall survival compared to standard Kasai surgery alone? Researchers will compare the group receiving UC-MSC in 2025-2027 with a historical control group of patients who previously underwent Kasai surgery without UC-MSC therapy.

Participants will:

Undergo preoperative evaluation, including laboratory and imaging tests. Receive Kasai surgery combined with intraoperative trans-portal vein injection of 20 million UC-MSCs.

Be monitored postoperatively through serial laboratory tests, imaging (Fibroscan), and clinical assessments at scheduled intervals.

Be followed up for potential serious adverse events and survival outcomes.

02

Conditions studied

  • Biliary Atresia
  • Kasai Portoenterostomy
  • Mesenchymal Stem Cell Transplantation
  • Liver Function Disorders
  • Liver Fibrosis
  • Survival Rate
03

In context

Biliary Atresia

78 studies on the registry are indexed under Biliary Atresia; 26 are open to participants now.

This study's planned enrollment of 14 is below the median of 45 across 43 interventional studies indexed under Biliary Atresia.

Browse Biliary Atresia studies →

Lead sponsor

Universitas Diponegoro is the lead sponsor of 23 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Days to 90 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants diagnosed with biliary atresia confirmed by intraoperative findings.
  • Underwent Kasai portoenterostomy at an age less than 90 days.
  • Parents or legal guardians have provided to participate in the study and follow all study procedures.

Exclusion criteria

Exclusion Criteria:

  • Infants with severe malnutrition.
  • Infants with major congenital anomalies other than biliary atresia.
  • Infants with positive tumor markers.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    Intervention Group (UC-MSC Group)

    Participants in this group are infants diagnosed with biliary atresia who undergo Kasai portoenterostomy before 90 days of age. During the operation, they receive intraoperative trans-portal vein injection of umbilical cord-derived mesenchymal stem cells (UC-MSCs) at a dose of 20 million cells diluted in 5 mL autologous plasma.

    Biological: Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs) · Procedure: Kasai Portoenterostomy

  • Placebo comparator
    Control Group (Historical Control Group)

    Participants in this group are historical patients who previously underwent Kasai portoenterostomy before 90 days of age at the same institution but did not receive UC-MSC therapy. Data for this group is collected retrospectively.

    Procedure: Kasai Portoenterostomy

Interventions

  • BiologicalUmbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)

    Intraoperative trans-portal vein injection of 20 million mesenchymal stem cells derived from umbilical cord tissue, suspended in 5 mL autologous plasma.

  • ProcedureKasai Portoenterostomy

    Surgical procedure to create a portoenterostomy for biliary drainage in infants with biliary atresia.

06

What researchers measure

Primary outcomes

  1. Serum Albumin Level

    Measurement of serum albumin as marker of liver synthetic function

    Time frame: Baseline (Pre-op), 4 weeks, 6 weeks, 12 weeks, 24 weeks, and 12 months post-operation

  2. Total Bilirubin Level

    Measurement of bilirubin levels (total, direct, indirect)

    Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months

  3. Gamma Glutamyl Transferase (GGT)

    Measurement of liver enzyme levels

    Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months

  4. Alanine Aminotransferase (ALT)

    Liver injury marker

    Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months

  5. Aspartate Aminotransferase (AST)

    Liver injury marker

    Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months

  6. Prothrombin Time (PT), aPTT, INR

    Coagulation parameters

    Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months

  7. Alpha Fetoprotein (AFP)

    Tumor marker

    Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months

  8. Alkaline Phosphatase (ALP)

    Liver and bone function marker

    Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months

  9. Lactate Dehydrogenase (LDH)

    Tissue injury marker

    Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months

Secondary outcomes

  1. Anemia Status

    Clinical and laboratory evaluation of anemia

    Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months

  2. Ascites

    Clinical evaluation via physical exam and ultrasound

    Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months

  3. Jaundice Status

    Clinical and laboratory bilirubin assessment

    Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months

  4. Pediatric End-Stage Liver Disease (PELD) Score

    Disease severity scoring system

    Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months

  5. Overall Survival (OS)

    Survival rate since intervention

    Time frame: From the surgery date up to the end of the study (12 months maximum follow-up)

07

Study locations

1 site
  • Dr. Kariadi General Hospital Medical Center
    Semarang, Central Java 50244, Indonesia
    • Avriana Pety Wardani, MD, Sp.BA · Contactavrianagarg@gmail.com · +62 81229515791
    • Avriana Pety Wardani, MD, Sp.BA · Principal investigator
    • Erik Prabowo, Dr, MD, M.Si.Med, Sp.B-KBD · Sub investigator
    • Kevin Christian Tjandra, MD · Sub investigator
    • Danendra Rakha Putra Respati, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — There is no plan to make IPD available. The individual participant data will not be shared due to privacy concerns and ethical considerations related to the protection of identifiable health information of pediatric patients. Data sharing is also restricted by institutional policy and local regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2025; primary completion for Apr 2026, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2025
First posted
Jun 8, 2025
StartEst.
Jun 17, 2025
Primary completionEst.
Apr 17, 2026
CompletionEst.
Apr 17, 2026
Last update
Jun 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07011199
Lead sponsor
Universitas Diponegoro
Responsible party
Avriana Pety Wardani (MD, Sp. BA, Dr. Kariadi General Hospital Medical Center) — Principal investigator
First posted
Jun 8, 2025
Start date
Jun 17, 2025 (estimated)
Primary completion
Apr 17, 2026 (estimated)
Completion
Apr 17, 2026 (estimated)
Last update
Jun 8, 2025

Study contacts

Avriana Pety Wardani, MD, Sp. BA
Contact
avrianagarg@gmail.com
+62 81229515791
Kevin Christian Tjandra, MD
Contact
kevinchristian2841@gmail.com
+62 87700771775
Avriana Pety Wardani, MD, Sp.BA
principal investigator · Dr. Kariadi General Hospital Medical Center
Erik Prabowo, Dr, MD, M.Si.Med, Sp.B-KBD
study director · Dr. Kariadi General Hospital Medical Center
Kevin Christian Tjandra, MD
study chair · Universitas Diponegoro
Danendra Rakha Putra Respati, MD
study chair · Universitas Diponegoro

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion